Accessibility options |
West London NHS Trust > Feedback and involvement > Research > Our studies

Our studies

This page lists a small selection of our ongoing clinical studies. If you would like more information about these studies or would like to take part, ask your clinician for more details or call 020 8354 8738 or email: research@westlondon.nhs.uk

SLEEP AND PSYCHOTIC FEATURES STUDY

People who suffer from mental health disorders often have difficulties regulating their mood and emotions.  They are also often troubled with disrupted sleeping patterns which can range from being unable to fall asleep, sleeping at the wrong time of day or having excessive sleepiness.  We are interested in finding out whether there is an association between difficulties in regulating mood and sleep. This study has therefore been designed to investigate the relationship between sleep and mood in people who have been referred to NHS mental health services in order to understand if sleep problems are present in these people. We will study measures of mood, feelings, sleep and life experiences.If you are interested in taking part please contact: Lauren.stevens@westlondon.nhs.uk
PPIP2

The immune system normally controls our ability to fight infection.  If the immune system goes wrong it may cause diseases called ‘autoimmune’ diseases. This study aims to understand if some psychiatric illnesses are caused by immune system problems in some people. We can diagnose some of these immune diseases using blood tests.  If your blood sample is positive for any tested antibodies we may contact you to invite you to take part in a treatment study. We may also wish to pass-on your details to our research partners who may ask you to attend for additional blood testing, memory testing, or brain imaging studies. This may allow more accurate monitoring of your disease but will not be an integral part of the study.If you are interested in taking part please contact: Karthikan.Yogarajah@westlondon.nhs.uk
100K GENOMES PROJECT

The Prime Minister launched the 100,000 Genomes Project in late 2012 in order to bring the predicted benefits of the study of genes and DNA to NHS patients.  The project is sequencing 100,000 genomes (genetic material) from families affected by rare conditions and from people with cancer. They aim to:

  • provide a diagnosis for some patients with rare diseases;
  • learn how to improve cancer treatment;
  • make new discoveries that will help us understand why some people get ill and others don’t;
  • develop future NHS healthcare services; and
  • support healthcare professionals and researchers to develop new medicines and tests.

If you have early onset or familial dementia and are interested in taking part, please contact: Lauren.Stevens@westlondon.nhs.uk
If you have early onset or familial schizophrenia and are interested in taking part, please contact: Karthikan.Yogarajah@westlondon.nhs.uk

ADULT AUTISM COHORT

At least 1% of all adults are on the autism spectrum.  However very little research has been undertaken into the life experiences of adults and older people on the autism spectrum and how these can be improved. In order to address this significant research gap in January 2015 a research programme began about the life experiences of adults on the autism spectrum and their relatives/carers. This project is being led by Newcastle University researchers and funded by the research charity Autistica and is about engaging adults on the autism spectrum and their relatives in research.If you are an adult living with autism, or the relative of someone with autism and are interested in taking part, please contact: Karthikan.Yogarajah@westlondon.nhs.uk

REMEDY

Lots of people who take medication to help with health problems like psychosis find that they get sexual problems.  Both men and women can be affected by sexual problems which may include a lower sex drive or getting less pleasure from sex.  Men may struggle to get or keep an erection.  Women may suffer from vaginal dryness even when they are sexually excited and some people are not able to reach orgasm.

At the moment we don’t know the best way to help people who have sexual problems that are associated with taking antipsychotic medication.  One possible option is to change to a different medication but we don’t know if this will help as it hasn’t been tested in a big research study.  In the REMEDY study we offer all people who have sexual problems that are associated with taking antipsychotic medication advice and support aimed at helping improve their sexual functioning.  In addition to this we arrange for half the people in the study to switch to a different medication and half to stay on their existing medication to see if there is a difference between the two groups.

If you are interested in taking part please contact: Lauren.stevens@westlondon.nhs.uk

European Prevention of Alzheimer’s Dementia – EPAD
Alzheimer’s disease is a progressive degenerative disease that results in a loss of brain cells.  It is the most common form of dementia in the elderly.  According to the World Alzheimer Report 2016, there were 46.8 million people worldwide living with dementia in 2015 and this number will reach 131.5 million in 2050.  There is now compelling evidence that Alzheimer’s disease takes hold in the brain decades before dementia symptoms appear, providing a window of opportunity for preventative intervention.  As a result, today’s research increasingly focuses on this pre-symptomatic phase, with the aim of delaying or preventing the disease.  This study is looking for healthy volunteers over the age of 50 to carry out a number of tests that determine predictors of risk for dementia.If you are interested in taking part, please contact: Genevieve.Morrison@westlondon.nhs.uk

EISAI – Early Alzheimer’s Dementia The purpose of the study is to find out if an investigational medicine called elenbecestat (E2609) is effective for the treatment of Early Alzheimer’s disease when compared with a placebo.  People with Alzheimer’s Disease or AD have an abnormal build-up of protein known as amyloid in their brain which is thought to lead to the memory loss and decline in other mental processes which worsen over time. Elenbecestat (E2609) is being developed to potentially reduce the amount of this protein build-up in the brain and thereby slow the progression of AD and the associated memory loss.If you have mild cognitive impairment due to AD, or mild AD and are aged between 50 to 85 years old, you may be suitable to take part.

If you are interested in taking part, please contact: Genevieve.Morrison@westlondon.nhs.uk